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Abstract
The peripheral nerve injury after trauma is a common occurrence in both human and 
veterinary medicine and has severe consequences for the survival and quality of life 
of the patients. Despite the continuous efforts and the creation of diverse medical and 
surgical techniques, the harmful effects of this type of injury are far from being over-
come. Regenerative medicine has been growing in the scientific milieu as a new ther-
apeutic approach for different situations. Among the cell-based therapies explored, 
the mesenchymal stem cells are evidenced by their features, versatility and potential 
applications. The olfactory mucosa mesenchymal stem cells, components of the olfac-
tory system and identified in the lamina propria, were newly identified and are still 
undergoing characterization, appearing as a new promise in the regenerative therapy 
of several tissues but with special emphasis on the nervous system in general and the 
peripheral nervous system in particular, for which they appear to have special regen-
erative aptitude.
Keywords: stem cells, mesenchymal stem cells, olfactory mucosa mesenchymal stem 
cells, peripheral nerve injury, regenerative medicine, biomaterials
1. Introduction
Peripheral nerve injuries (PNI) lead to serious consequences in the life of the injured, impair-
ing the performance of physiological functions and occupational activities [1]. The causes of 
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PNI are multiple and varied and may include traumatic events and iatrogenic interventions. 
In this second group, the peripheral nerve can be injured during manipulation of the nerve 
with different surgical instruments, due to poor nerve exposure during the procedure, during 
removal of tumours or lymph nodes, due to the inexperience of the surgeon and even during 
removal of osteosynthetic devices [2]. The main consequences of this type of injury are the 
loss of motor, sensory and autonomic function in the denervated body segments, resulting in 
substantial functional deficits [3].
When compared to the central nervous system (CNS), the peripheral nervous system (PNS) 
presents a higher reparative and regenerative activity. This contrast in the regenerative capac-
ity depends on the intrinsic characteristics of the injured neurons of CNS and PNS and also on 
the physiology and functional environment of the two systems [4]. The ability of regeneration 
also depends on the age of the injured, the mechanism of injury and, particularly, survival 
and functional status of neural cell bodies [5]. Nevertheless, poor functional recovery is com-
mon due to chronic Schwann cell denervation, chronic neuronal axotomy and misdirection of 
regenerating axons into wrong endoneurial tubes. The effect of muscle denervation atrophy is 
secondary to the nerve injured and most of the times, implies fibrosis and neurogenic atrophy 
of the muscle [6].
Peripheral nerve damage not only removes a source of sensory input from the somatosensory 
system but also triggers a set of modifications in the neural circuits that lead to long-term 
changes in spinal somatosensory functions [7]. In fact, one of the worst consequences of PNI 
is the development of neuropathic pain characterized by allodynia and pain hypersensitivity 
in the partially denervated region [7, 8].
Peripheral nerve lesions can vary widely in severity and in most cases do not show complete 
recovery with the injured individual suffering from chronic lifelong disabilities. Satisfactory 
outcomes are usually limited to relatively minor injuries [9]. Even rapidly intervened patients 
are likely to undergo prolonged denervation in the distal segment of the injured nerve due to 
the slow rate of regeneration [10].
Achieving better outcomes depends on the advancements in microsurgical performances, 
introduction of new techniques into clinical practice and improvement of the therapeutics 
options already in use [11]. Tissue cell therapy and mesenchymal stem cells (MSCs) has 
been proposed as a promising alternative to treat a variety of neurologic injuries. The use 
of MSCs that can differentiate into appropriate cell types in the affected area or can secrete 
important growth factors that promote the regeneration process and positively modulate the 
local inflammatory response has developed rapidly in the last years [12]. Although MSCs’ 
functional mechanisms are still poorly understood, nasal olfactory mucosa mesenchymal 
stem cells (OM-MSCs) stand as a promising competitor for therapeutic application due to its 
advantages [13].
This chapter will focus on the phenomena of PNI and its nuances, on the characteristics of 
OM-MSCs, their secretome and current applications. Finally, the potential use of these MSCs 
associated with biomaterials in cases of nerve damage, a tissue engineering technique that has 
not been applied until today, will be explored.
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2. Peripheral nerve injury
2.1. Nerve functional anatomy
The peripheral nerve is composed by sensory and motor neurons whose long axons communi-
cate with distant target organs [14]. The cell bodies of sensory neurons are located in the dorsal 
root ganglion while those of the motor neurons are found within the CNS, into the spinal cord 
or brainstem [15]. Its coating is complex and consists of three distinct layers (Figure 1). The 
axons are directly involved by a connective tissue sheath named endoneurium whose mechani-
cal load is reduced. A fine network of capillaries exists in association with the endoneurium. 
Groups of axons involved by endoneurium, which together form the nervous fascicles, are cov-
ered by perineurium, a thin but dense epithelial layer. The perineurium offers strength in ten-
sion, and also maintains the blood-nerve barrier and endoneurial homeostasis [16]. Groups of 
fascicles are contained within the peripheral nerve surrounded by a connective tissue layer 
called epineurium that comprises 50% of the total cross-sectional area of the peripheral nerve. 
The inner epineurial layer separates fascicles, contains the vessels supplying and coursing 
through the nerve and a small amount of adipose tissue. The external layer surrounds all the 
fascicles, protects and defines the nerve anatomically [14, 17]. The endoneurium is longitudi-
nally oriented while the perineurium and epineurium are circumferential (Figure 1) [18].
2.2. Nerve injury: pathophysiology
Mechanisms of PNI can be divided into three categories: mechanical (traumatic), vascular (isch-
emic) or chemical (neurotoxic) [19]. Mechanical processes can occur due to a sufficiently aggres-
sive trauma, iatrogenic or not, due to perforating injuries with needles or due to administrations, 
Figure 1. Schematic representation of the peripheral nerve structure and anatomical overview of the PNS. Axons, 
surrounded by myelinating Schwann cell sheaths, are enclosed by endonerium. Next, the perineurium binds individual 
axons together to form fascicles. Several axons are contained in each fascicle. Lastly, epineurium groups fascicles to one 
another, forming the nerve cable. Endoneurium, perineurium and epineurium present a tubular shape.
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such as anaesthesia, on the periphery or into the nerve itself [20]. Nerve compression may trig-
ger a blockage in nerve conductivity and, if prolonged, cause focal demyelination of the axons, 
ischemic phenomena, increased neuropeptide production [21] and increased spinal dorsal horn 
circuits activity that are involved in sensory information processing, including pain perception 
[22]. Stretch lesions are generally associated with intense exercise and fractures in the extremi-
ties where there is a close contact between the bone and nerves. Peripheral nerves exhibit intrin-
sic elasticity due to its collagen content at the endoneurium, but a strong enough force can lead 
to stretch injuries, resulting in a complete loss of continuity with nerve avulsion. Despite this, 
in some cases, continuity is maintained [21, 23]. Nervous lacerations or transections, caused by 
sharp objects, are common and represent about 30% of the identified cases. These lesions can 
result in complete transections or maintenance of structural continuity [24].
Vascular damage during nerve injury can lead to local or diffuse ischemia, occlusion of the 
arteries from which the vasa nervorum is derived or haemorrhage occurring within the nerve 
sheats. This vascular dysfunction and consequent hypoxia, contributes to the manifestation 
of neuropathic pain [25]. The epineural circulation is constituted by plexuses of microvessels 
running longitudinally in the epineurium that sends transverse branches through the perineu-
rium to form a vascular network consisting primarily of capillaries in the endoneurium. It is of 
central importance and any alterations can reduce the nervous blood supply to residual lev-
els. The connective tissue of the internal epineural layer makes the vessels less susceptible to 
compression since the forces are not directly transmitted to the epineural vessels. Sufficiently 
intense traumatic forces increase the permeability of epineural vessels and even larger forces 
or prolonged compressions can also injure endoneurial vessels, leading to intrafascicular 
oedema and secondary nerve damages [21]. Local anaesthetics and adjuvants also reduce 
blood flow, depending on both the agent used and its concentration [26].
Chemical lesions originate in the toxicity of solutions injected directly into the nerve or adja-
cent tissues, with development of acute inflammatory reactions and chronic fibrosis involving 
the nerve [27]. The site of administration (extraneural, intraneural, interfascicular or intrafas-
cicular) determines the degree of toxicity and the same substance administered at different 
sites or portions of the nerve can cause different toxicity and lesions [28].
Before regeneration begins, a series of degenerative processes must occur, a direct prelude 
to the regenerative process. Regenerative success depends on the severity of the lesion and 
subsequent degenerative changes [21]. Any structural change or defect in the axon or its 
phospholipid bilayer leads to a programmed cascade of cell death that is interrupted only 
if there is rapid repair. Axonal degeneration follows a sequence of events that prolifer-
ate both proximally and distally to the site of injury. Axons disconnected from their cell 
bodies undergo degeneration through phenomena of chromatolysis [29]. Once the nerve 
is injured, its distal portion begins to degenerate due to the activity of proteases and the 
functional disruption of metabolic resources of the nervous cell body, in a calcium-medi-
ated process known as Wallerian degeneration that involves invasion by myelomonocytic 
cells and results in the destruction of myelin and the onset of mitosis in Schwann cells 
(Figure 2). The degeneration of the distal axonal endings occurs due to autolytic mecha-
nisms. The proximal end of the nerve swells but suffers minimal damage associated with 
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retrograde degradation. The cytoskeleton starts to breakdown, followed by the dissolution 
of the cell membrane [30]. Once the cytoskeleton and membrane degrade, the Schwann 
cells that surround the distal portion of the axon shed their myelinated lipids. Axonal and 
myelinic debris are then removed by cells with phagocytic activity such as macrophages 
and Schwann cells which also release interleukins-6 to stimulate other Schwann cell and 
fibroblast proliferation (Figure 2) [31].
After removal of the debris, the regenerative process begins at the proximal end of the injured 
nerve and extends to the distal end. The new axonal buds (50–100) emanate from the most dis-
tal Ranvier nodes, the non-myelinated areas of the axon localized between the Schwann cells; 
these, in turn, guide the new cytoplasmic axonal extensions between basal membranes of the 
two nerve ends [32]. Proteases are also released from the growth cone to aid axonal regenera-
tion through tissue. Several axonal extensions develop from the growth cone to contact the 
receptor at the distal end. The remaining neurites are abraded; otherwise, they continue to 
grow disorganized and may lead to neuromas that manifest clinically as painful nodules [14]. 
This process, however, is not free of complications. Uncontrolled branching or misdirecting 
of growing axons and dysfunctional innervation of target organs are common occurrences 
(Figure 2) [8]. Disruption of motor or peripheral targets secondary to PNI decreases the corti-
cal representation of this zone in the ipsilateral cerebral hemisphere. Thus, adjacent regions 
in the ipsilateral hemisphere and regions of the contralateral hemisphere overgrow to com-
pensate for deficits. The interpretation of the stimuli becomes unpredictable between regions 
associated with the lesion and healthy regions, which may lead to phenomena of neuropathic 
pain and phantom limbs [33]. In humans and rodents, axon regeneration occurs at a slow rate 
of 1–2 mm/day. Thus, significant injuries can take months to heal [34].
2.3. Nerve injury grading system
Success in regenerative processes after PNI depends directly on the severity of the lesion. 
Grading systems were developed in order to correlate the microscopic changes of the injured 
nerve with the clinical manifestations and prognosis. The first classification system of nerve 
injuries in three categories was proposed by Seddon in 1943 [35]. In this system, neuropraxia 
Figure 2. Schematic representation of the Wallerian degeneration.
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is the least severe injury, without loss of nerve continuity: axons are anatomically intact, but 
nonfunctional. Since the affected nerve is unable to transmit impulses, the corresponding 
body regions become paralyzed. The lesion is followed by a temporary paralysis due to a 
local ion-induced conduction block and ischemia at the injury site, with a consequent recov-
ery. Usually, no signs of Wallerian degeneration or regeneration are identified, but subtle 
alterations in myelin structure can be found and lead to motor and sensory loss due to seg-
mental demyelination. Functional changes remain until re-myelination occurs. If decompres-
sion disappears, complete recovery is expected, without any intervention, within 3–6 months. 
Axonotmesis, the second level of injury, is characterized by a complete disruption of the axon 
and surrounding myelin while structures of supporting connective tissue, namely the perineu-
rium and epineurium, remain intact. Axon and myelin degeneration occur distal to the point of 
injury by Wallerian degeneration, causing complete denervation (Figure 2). Despite this, once 
the integrity of the collagenous structures involving the nerve and that function as guides to 
growth of new axonal buds is maintained, the prognosis of recovery is excellent with a recov-
ery rate of 1 inch per month [35, 36]. Neurotmesis results in a total disconnection between the 
two ends of the injured nerve. The functional loss is complete and recovery without surgical 
intervention or any other alternative is unlikely due to the intense scarring phenomena and 
loss of the collagen coatings and their guide function to axonal regrowth [35, 37].
In 1951, Sunderland proposed the existence of five categories in PNI according to its sever-
ity (Figure 3) [38, 39]. First- and second-degree injuries are equivalent to Seddon’s neura-
praxia and axonotmesis respectively. Third-degree lesions refer to a total disruption of the 
axon (axonotmesis) but are associated with partial lesions of the endoneurium. This category 
is placed between axonotmesis and neurotmesis in Seddon´s classification. The recovery 
prognosis depends on the extension of the endoneurial lesion and usually occurs over many 
months with conservative treatment or surgery to release the entrapment sites over the swol-
len nerve with or without limited neurolysis. Sunderland further divides neurotmesis into 
fourth or fifth-degree lesions. In fourth-degree lesions, all portions of the nerve undergo dis-
ruption with the exception of epineurium and internal haemorrhage and fibrous tissue impris-
ons the growing nerve sprouts due to fascicular discontinuity, inhibiting the axonal growth 
and originating neuromas-in-continuity. In fifth-degree lesions, the epineurium is also injured 
and the formation of end-bulb neuromas is observed. In both cases, recovery without surgical 
or similar intervention is impossible (Figure 3) [8, 36, 39].
Finally, Mackinnon and Dellon described a sixth-degree for mixed lesions. This degree is 
based on the evidence that a single trauma can affect different regions of the nerve transverse 
session variably, causing different degrees of injury at different points of the same nerve. 
Presumably, this is the most common type of injury, especially in perforating lesions, and 
is associated with bone fractures. Recovery and treatment vary according to the degree of 
injuries observed [17, 39].
2.4. Nerve repair and therapeutic options
Primary nerve repair through micro sutures is still the standard method in cases of axonot-
mesis and neurotmesis. The procedure should be performed immediately after the injury 
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or within a short period of time. Epineural repair is performed when a tension free coap-
tation in a well-vascularized bed is achieved. The surgical procedure may be divided into 
distinct phases. In the preparation phase, the nerve ends are prepared to get viable nerves 
without necrotic tissue. In the approach phase, the nerve ends are coaptated in order to leave 
a minimum gap between them. This gap will be rapidly filled with blood clots, and a fibrin 
Figure 3. Schematic representation of the Sunderland classification of peripheral nerve injuries. More recently, 
Mackinnon and Dellon have proposed a sixth-degree for mixed lesions, based on the evidence that a single trauma can 
affect different regions of the nerve transverse session variably, causing different degrees of injury at different points of 
the same nerve.
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matrix containing macrophages serves as a transport medium for Schwann cells between the 
proximal and distal nerve segments. Axons of the proximal segment grow in association with 
Schwann cells. In order to maintain the coopted position, interrupted microstructures are 
performed (neurorrhaphy) in the epineurium, always ensuring the physiological position of 
the segments after suturing and avoiding rotation of the nerve ends [40]. Another surgical 
technique, more suitable for larger nerves includes an intranerve dissection and suture of 
fascicular groups. This technique allows a better fascicular alignment but causes more trauma 
and intranerve scarring due to the permanent presence of the suture [41].
Procedures connecting uninjured nerves to the distal portion of an injured nerve (neurotisa-
tion) are sometimes employed if direct repair of the injured nerve is not possible. A healthy 
nerve transfer and coaptation in cases of nerve root avulsions, as well as reimplantation of an 
avulsed nerve root, are also possible techniques [11].
When the injury originates a gap too large to perform a neurorrhaphy, a graft or nerve conduit 
may be used to provide a guidewire for the growing axons. Autologous nerve grafts are most 
indicated since they have all the microstructural components that facilitate axonal migra-
tion and have no antigenic components, but the collection of nerves with adequate diameter 
and the consequences of sacrificing a healthy nerve are important limitations [42]. Allografts, 
generally from cadaveric donors, despite providing the necessary cellular structures, require 
immunosuppressive treatments for long periods of time in order to prevent rejections in the 
receptor [43]. The allografts can be enzymatically processed to become acellular, thus alle-
viating the need for immunosuppression, presenting high success rates compared to other 
techniques. Even so, inflammatory reactions can, even rarely, lead to scarring phenomena 
that preclude normal nerve regeneration [44, 45].
Nerve guidance conduits (NGCs) have been used as viable alternatives to the grafts in a tech-
nique called entubulation or tubulisation [45] that allows the entrapment of the fibrous tissue 
around the injury site and the local maintenance of the neurotrophic and neurotropic factors 
secreted in the damaged nerve ends [44]. Since they do not have the microstructure of the 
nerves, can only be used in defects with no more than 10 mm if these tube-guides are not 
associated with cell-based therapies or growth factors local delivery. Due to this fact, more 
attention has recently been paid to its effectiveness in assisting coaptation than to its direct 
function in repairing the gap. They are usually applied to smaller nerves and overcome the 
disadvantages of the organic options [45]. To ensure its functionality, the characteristics of 
the NGCs used must comply with all the criteria established for this type of biomaterials: 
the material used must be (i) biocompatible with the regenerating tissue where it will be 
applied and should never trigger any local or systemic inflammatory response [46]; (ii) bio-
degradable, while ensuring mechanical and architectural stability during the regenerative 
process and resisting to the application of sutures and to inflammatory tissue reaction [47]; 
(iii) flexible and resistant in a balanced way in order to avoid compression of the regenerating 
axons and to limit tissue inflammation [48]; (iv) capable of preventing the growth of excessive 
fibrous tissue associated with the site of injury and reducing the loss of neurotrophic factors 
secreted by damaged nerve endings [44]; (v) capable to provide an orientation line to the 
growth cone through a 3-D tubular structure, thereby diminishing misdirection phenomena 
Mesenchymal Stem Cells - Isolation, Characterization and Applications84
[49]; (vi) semi-permeable and with pores of adequate diameter that allow the influx of oxy-
gen and interstitial nutrients to nourish the growing axon that simultaneously prevent the 
entry of inflammatory cells and the loss of growth factors [50]; technically efficient, ensuring 
requirements related to production, sterilization, storage and handling [51]. Adapted in each 
case, these biomaterials must have appropriate dimensions that allow the connection of the 
nerve defects without tension, and the diameter of the conduit and the thickness of the wall 
should be sufficient to accommodate the two stumps at the nerve ends without any compres-
sion being exerted. In fact, these dimensional variations seem to have an influence on the 
rate of nerve regeneration [52]. Various materials can be used in nerve conducts, which can 
be divided into non-resorbable devices, natural resorbable devices and synthetic resorbable 
devices.
Non-resorbable devices with synthetic origin, or polyvinyl alcohol hydrogels, consist of water 
in proportions identical to those observed in biological tissues and in polyvinyl alcohol (PVA) 
that guarantees mechanical structural stability and facilitates sterilization [53]. In contrast, the 
nature of these materials creates problems related to compression and tension at the suture 
lines, even after nerve regeneration has occurred. In addition, there are still few clinical stud-
ies evaluating the efficacy of these materials in controlled and randomized models [44].
Resorbable devices with natural origin include type I collagen based devices, a natural and 
abundant organic component that can easily be isolated and purified to reduce its antigenicity 
[54]. Its reabsorbability can be defined to varying degrees and its adhesiveness allows cell sur-
vival and proliferation for long periods of time [55]. With proven biocompatibility and ability 
to support and guide tissue regeneration in vivo, these devices have already demonstrated 
efficacy in large gaps as recorded in the literature [56]. The main disadvantages related to 
the use of these materials are discrepancies observed between the different products avail-
able in the market with respect to the months needed to complete biodegradation and the 
observation of immune responses that require the use of immunosuppressive drugs. [57]. 
Furthermore, there is evidence that materials of different lots can lead to different results, 
hindering reproducibility, degeneration intervals can be increased and the regenerative sup-
porting ability of the stored nerve may be compromised [58].
Synthetic scaffolds have recently been developed with cellular guidance channels that facili-
tate propagation of Schwann cell processes, which may improve the chances of successful 
nerve regeneration (Figure 4) [11]. Poly(l-lactide): poly (glycolide) (PLGA) and poly(dl-
lactide-ε-caprolactone) (PLC) subgroups may be included in this group of resorbable devices 
with synthetic origin. The biomaterials of the first group are characterized by good levels 
of degradability, mechanical properties and associated cellular viability, having good per-
formance in clinical trials with gaps of considerable dimensions. In contrast, high rates of 
acidic degradation and their products, rapid changes in mechanical properties and low solu-
bility are important limitations [59]. PCL biomaterials are characterized by being transparent, 
which brings great clinical advantages during surgical application across the nerve gap defect 
[60], besides demonstrating efficacy in cases of large gaps [44]. Among the limitations, it is 
worth mentioning its high rigidity, which requires immersion in saline solution prior to use. 
In addition, it is necessary to use needles of larger dimensions and more resistant during the 
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application of sutures [50]. Other complications include foreign body reactions, severe swell-
ing with possible device lumen obstruction, fragmentation due to incomplete degradation, 
early collapse of the device with possible formation of neuromas, and reduced number of 
myelinated nerve fibres connecting the gap defect [61, 62].
Nerve sheaths constituted by collagen extracellular matrices, acellular and animal-derived, 
namely with origin in swine intestinal submucosa, have already been used with relative success 
in the regeneration of different tissues and as nerve guidance channel for regeneration of the 
peripheral nerve [63]. This technique supports early neovascularization and acts as scaffold in 
Figure 4. Schematic representation of a tube-guide that can be implanted in neurotmesis injuries (a). Tube-guide made 
of poly(lactic acid) (PLA)-gelatin piezoelectric material implanted the sciatic nerve of a rat, used as animal model for 
studying the nerve regeneration process (b). The sciatic nerve of the rat where the neurotmesis injury was reconstructed 
with an end-to-end suture (c). Scanning Electron Microscope (SEM) image of the inner and outer diameter of a tube-
guide made of PLC (transversal section; 1500×) (d). A tube-guide made of PLGA (e). PVA tube-guide; PVA tube-guide 
loaded with carbon nanotubes (CNTs), and PVA tube-guide loaded with poly-pyrrole (PPy) (f).
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axonal regeneration without immunogenicity problems. In addition, its use guarantees the pres-
ence of several growth factors and cytokines that also aid in neuronal survival and growth [64].
Neurotrophic factors, secreted by neuronal or non-neuronal cells in the proximal and distal 
nodes of the injured nerve, are essential in the conduction of the regenerative process. The 
addition of these factors to the wall or lumen of the conduits and their slow release by dif-
fusion at the lesion site are techniques currently applied and without which the synthetic 
conduits may fail to aid the regenerative process over longer graft lengths [65]. Among the 
neurotrophic factors identified and commonly used are transforming growth factor, beta 
superfamily, nerve growth factor, insulin-like growth factors, neurotrophins 3, 4, and 5, 
ciliary neurotrophic factor, neuregulin-1, brain-derived neurotrophic factor, glial cell line-
derived neurotrophic factor [63] and platelet-rich plasma [66].
Cell-based therapies have been proposed as a promising alternative to treat a variety of neurologic 
injuries and the use of stem cells that can differentiate into appropriate cell types in the affected 
area has developed rapidly in the last years [67]. Stem cells are undifferentiated cells capable to 
proliferate and produce both new stem cells and different types of cells and tissues [68]. More 
specifically, MSCs are multipotent, heterogenic stromal cells derived from the mesoderm [69], 
one of the two populations of bone marrow progenitors (bone marrow stromal progenitors), 
and were initially characterized as presenting adherence to plastic culture dishes, fibroblast-like 
morphology and a unique ability to differentiate into multi-lineage MSCs, phenotypes and spe-
cialized tissues [70]. Due to the attention that these cells have received in recent years, it became 
necessary to create a more precise definition that unified the basic characteristics of the MSCs, 
which emerged in 2006 by the International Society for Cellular Therapy. Thus, MSCs [71]:
• are plastic-adherent under standard culture conditions (α minimal essential medium plus 
20% fetal bovine serum);
• express non-specific markers CD105, CD90 CD73 and CD44, and lack the expression of 
hematopoietic lineage markers CD45, CD34, CD14 or CD11b, CD79α or CD19 and major 
histocompatibility complex- (MHC-) II/human leukocyte antigen- (HLA-) DR
• are capable to in vitro differentiate into at least three different cell types, like osteoblasts, 
adipocytes and chondroblasts.
While this initial definition is broad enough to cover the most obvious features of MSCs, 
several studies over the years have shown that these cells are able to differentiate not only 
in osteoblasts, adipocytes and chondrocytes but also in other cells and tissues with meso-
dermal origin (ligaments and tendons, cardiomyocytes, muscle) and also ectodermal and 
endodermal origins (skin, retinal epithelial pigment, lungs, hepatocytes, renal tubules, 
pancreatic islets, sebaceous gland ducts and neural cells) [68]. MSCs can be obtained from 
a vast array of tissues that include adipose tissue, lungs, bone marrow, umbilical cord 
(Wharton's jelly and umbilical cord blood), synovium, amniotic fluid, fetal blood, dental 
pulp, skeletal muscle, circulatory system [68, 69] and olfactory mucosa [13]. Applied to 
regenerative medicine, MSCs present exceptional features that make them great options, 
such as easy expansion, differentiation into different cell types, immune-privileges and 
immune modulation, tropism to injured sites, trophic stimulation and modulation of 
 tissues functions [46]. In addition to being able to secrete neurotrophic factors and provide 
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an environment conducive to neurogenesis and proliferation of Schwann cells in nerve injury 
sites, they can themselves differentiate into cells with Schwann cell phenotype and modulate 
the local inflammatory process and the Wallerian degeneration [72], being a precious addition 
to the use of biomaterials and growth factors in therapeutic techniques after PNI.
3. Nasal olfactory mucosa mesenchymal stem cells
3.1. General features
The olfactory mucosa (OM), as a component of the olfactory system, consists of different 
types of cells. Among these are olfactory neurons (ON) that are able to regenerate continu-
ously throughout adult life. This regenerative capacity is attributed to olfactory stem cells 
and supporting cells of OM, together promoting axonal regeneration [73]. In addition to the 
bipolar ON or olfactory neurosensory cells, several cell types can be identified in the OM: 
horizontal basal stem cells (HBCs) and globular basal stem cells (GBCs) in the olfactory epi-
thelium, MSCs in the lamina propria, olfactory ensheathing cells (OECs) and support cells 
(Figure 5). New nerves generate from GBS in the olfactory epithelium, which are guided to 
their correct position in the olfactory bulb by OECs in the olfactory mucosa. GBCs, derived 
from HBCs, were initially thought to be the exclusive source of ON and support cells [74] 
but it is currently known that MSCs are also capable of producing neurons in vitro [75].
The OM-MSCs were initially identified from an embryonic rat OM culture [76] and the first 
characterization studies evidenced the expression of mesenchymal-specific markers such as 
CD90, CD105, STRO-1 and differentiation into the three main cell lines [74, 77]. OM-MSCs 
have important characteristics such as neural crest origin, high versatility, vast distribution, 
advantageous localization and are not susceptible to chromosomal abnormalities or tumori-
genicity [78]. They exhibit high mitotic activity when compared to the bone marrow MSCs 
(BM-MSCs) (nearly three times higher) and are able to self-renew in long-term cultures (over 
15 weeks) by maintaining telomerase activity and lack apoptotic activity [79]. The olfactory 
mucosa itself is a great cell source since its renewal continues throughout life and OM-MSC 
potency is not even affected by the age of the donor [80]. Different from BM-MSCs, OM-MSCs 
promote CNS myelination and induce the differentiation of neural stem cells into oligoden-
drocytes and oligodendrocyte maturation. All that suggest an easy and rapid propagation to 
sufficient levels that allow transplantation and that MSCs from a more neurogenic niche may 
have different properties to the classical BM-MSCs [81, 82].
Due to its origin from ectoderm (resulting from the interaction between cranial neural crest 
and olfactory placodes) and its high expression of neural cell-related genes, it was proposed 
that OM-MSCs be renamed as ectomesenchymal stem cells [81]. Even its origin highlights the 
predisposition for OM-MSCs to differentiate into neural lineage cells.
3.2. Isolation, characterization and differentiation
The properties of the OM-MSCs are still far from being fully understood. Located in the olfac-
tory region of the nasal cavity, OM-MSCs are primarily derived from neural crest cells, have 
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a high proliferation rate, self-renewal ability and multiple lineage differentiation capabilities 
[83]. These cells have already been isolated from human and mice [84], rat [85], rabbit [86] and 
dog [87], both with in vivo [84] and post-mortem protocols [86].
The described collection methods include a delicate discarding of the turbinates [82, 88] or 
complete collection of the olfactory bulb [80], being the harvested material taken in balanced 
solutions containing antibiotics and antifungals [82]. The olfactory epithelium or olfactory 
bulb tissue sample is then cut into small pieces, digested with collagenase and DNase [80, 
82] or dispase [78] to separate the cells from their extracellular matrix. Then, they are cul-
tured in flasks containing appropriate medium like Dulbecco’s modified Eagle’s medium or 
HAM´s F-12 supplemented with fetal calf serum or fetal bovine serum, antibiotics, antifun-
gals and growth factors [75]. After removal of non-adherent cells, the remaining cells can be 
trypsinized, expanded [82, 88] and then banked in liquid nitrogen or induced to form for dif-
ferentiation. [89]. Multilineage differentiation can be achieved by culturing under induction 
conditions and staining with specific dyes [88].
Determination of the phenotypic markers is achieved through flow cytometric analysis where 
single cell suspensions are stained with specific fluorochrome-conjugated antibodies [78, 80], 
RT-PCR [80] or by immunocytochemistry [82]. In addition, the identification of specific pro-
teins of these cells can be performed using immunofluorescence microscopy [88].
In colonies formed after culture, OM-MSCs exhibit mostly fibroblast-like morphology [78, 80, 88, 
90]. Phenotypic analysis reveals the presence of Stro-1 [75–77], CD29 [80, 88], CD44 [80, 88], CD49b 
Figure 5. Schematic representation of the olfactory mucosa and relative location of its cells.
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[90], CD54 [13, 77, 82], CD73 [77, 82, 90], CD90 [13, 75–78, 80, 82, 88, 90], CD105 [13, 75–78, 80, 82], 
CD106 [77, 78] and CD166 [77, 78, 80, 82, 90] markers and the absence of haematopoietic stem cell 
markers such as CD34 [13, 75–78, 80, 88, 90], CD45 [13, 75–78, 80, 88] and CD11b [88]. Strangely, 
one work indicates lack of Stro-1 [82]. Immunofluorescence microscopy provides evidence for 
the expression of neural stem cell–related proteins such as vimentin [88], nestin [75–77, 81, 82, 88] 
and also NG2 [77, 81], a marker whose presence indicates the ability to form neurospheres and to 
generate neurons in vivo and in vitro [81]. They also express p75-NTR and SMA [77]. Consistent 
with the characteristics of multilineage differentiation capacity of MSCs, OM-MSCs can be differ-
entiated into osteocytes and adipocytes [13, 82, 88], chondrocytes [78, 90], neuron like cells [13, 78, 
81] and myocardial-like cells [80] when cultured under appropriate conditions. They, therefore, 
present abilities to differentiate into mesodermal and ectodermal cell types.
3.3. Secretome and metabolome
It is known that the regenerative effect of MSCs, as well as OM-MSCs, is not exclusively 
related to their differentiating ability but also to paracrine factors. These are important in the 
creation of a support microenvironment that allows cellular survival, differentiation, activa-
tion of endogenous neural stem cells, reduction of the inflammatory reaction and induction 
of angiogenesis [91]. MSCs have also the ability to produce potent protective factors that pro-
mote tissue repair and immunomodulation, reducing fibrosis and cell death [92]. The determi-
nation of the characteristics and components of the secretome and metabolome of a given cell 
is essential to uncover the essential needs for its success in regenerative processes [93]. Similar 
cell types with different secretome profile can reflect their cellular niches and local function. 
The only study of the determination of the secretome and metabolome of OM-MSCs allowed 
to identify 274 proteins in OM-MSCs conditioned medium and the identification of some pro-
cesses that are usually associated to transplantation processes such as biological regulation, 
cellular processes, metabolic processes, development processes and response to stimuli [13]. 
These processes promote repairing by facilitating migration to injured sites, remodelling the 
extracellular matrix and increasing metabolism and cellular activity. In the OM-MSCs, genes 
related to cell growth and migration, angiogenesis and blood circulation, inflammatory and 
immune regulation and neurotrophy, the major components of transplantation and regenera-
tive promotion, were identified and they can also produce cytokines that promote hemato-
poietic stem cell survival, proliferation and differentiation [90]. In addition, it has also been 
identified the secretion of important molecules in neural differentiation such as Dystroglycan 
that can organize axon guidance cue location which is critical for nervous system develop-
ment and plays important roles in perisynaptic and axonal matrix formations, contributing 
to synaptic homeostatic plasticity [94]. Proteins like Dermcidin, retinoic acid induced 1 and 
cadherin 13 that contribute to cell cycle related events and play roles in neural differentiation 
were also identified. Dermcidin acts as a neural growth factor [95]; retinoic acid is involved in 
neurobehavioural disorders and plays a role in normal neural development [96] and Cadherin 
acts as a regulator of neural cell growth [97]. OM-MSCs were identified as secreting high levels 
of the chemokine CXCL12 [98] that is known to be important in the promotion of endogenous 
myelinations [99]. Evidences that OM-MSCs are capable to alter the biological properties of 
the precursors of OECs and oligodendrocytes and of increasing the myelination of the oligo-
dendrocytes in the CNS [63], in conjunction with the other findings referred, demonstrate the 
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enormous potential of these cells to be applied in regenerative medicine of the nervous system 
in general and in the PNS in particular.
3.4. Applications
The studies and characterizations carried out to date suggest that the OM-MSCs have pheno-
types and differentiation characteristics similar to other MSCs and can efficiently proliferate 
in culture. However, studies of direct clinical application of these cells in regenerative thera-
pies are still few and the results obtained need more research and deeper approaches.
Several studies have demonstrated the improvement of locomotor function in animal and 
human patients with spinal cord injury after implantation of entire OM grafts and OECs [100] 
but isolated OM-MSCs have never been used singly in this type of cell therapies [73]. In these 
cases, the effect of OM-MSCs may be masked by the use of OM as a whole, making it impos-
sible to determine the direct effect of MSCs on motor recovery. Despite this, it has been already 
demonstrated that OM-MSCs promote rat CNS myelination in vitro [77]. A study on the use of 
cell-based therapy in cases of deafness revealed that OM-MSCs present repair efficiency in the 
spiral ganglion neuron after lesion induction in the cochlea [101]. Transplantation of OM-MSCs 
into a brain after injury led to a partial reconstitution of the hippocampus, with observation of 
important phenomena such as migration of stem cells to the inflamed region, in situ neuronal 
differentiation and local stimulus to neurogenesis. The injured individual presented reversal of 
learning deficits, recovered memorization capabilities and enhanced physiological function. All 
these events are also observed if the OM-MSCs were transplanted directly into the cerebrospi-
nal fluid. These results open precedents for the use of OM-MSCs in patients with post-traumatic 
memory loss [102]. Another study has shown that OM-MSCs generated dopaminergic cells and 
reduced the asymmetries resulting from the ablation of dopaminergic neurons when trans-
planted into a rat brain model of Parkinson's disease, also opening precedents [103] for its use in 
neurodegenerative diseases [104]. Recently, immunoregulatory properties of OM-MSCs have 
been identified, which can exert immunosupressive functions and modulate T-cell responses. 
These findings indicate a potential use of these cells targeting autoimmune diseases [88, 105].
It is possible that in some studies in which olfactory mucosa cells were used without an exact 
determination of the cell types present in the heterogeneous cell mix, OM-MSCs were part of 
the group used and performed specific actions. In these cases where there is no detailed deter-
mination of the composition of the cell matrix used, it is impossible to know which type of 
cell has dominant function or effectively reparative properties. For instance, a study in which 
transplantation of OM to rat hearts after infarction led to differentiation into cells resem-
bling cardiomyocytes, but failure to specify the types of cells included in the transplantation 
makes it impossible to attribute regenerative function to OM-MSCs and makes it difficult to 
optimize future procedures [106]. The use of unpurified olfactory mucosal cells cannot be 
directly compared to purified OM-MSC and it is essential that each type of transplanted cell 
is characterized prior to the procedure. Even the preliminary study of the use of OM-MSCs in 
the treatment of Parkinson's disease resulted from the use of the OM as a whole and not from 
the MSCs isolated [103]. The combined use of cells is not, obviously, a wrong procedure and 
it has already been shown that the combined use of OECs and OM-MSCs has beneficial effects 
of inter-stimulation between cells with respect to their functionality and secretome [106, 107]. 
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It is, however, important to define exactly the role of each of them in the regenerative process 
before its use on a larger scale. At this point, and given the existing knowledge about the func-
tional characteristics of OM-MSCs, the experience obtained in the few realized studies and the 
potential that has been established for these cells, is important to set specifc goals and start 
more focused works to determine the importance of these cells in the future of regenerative 
medicine, in the approach to lesions of the peripheral nerve as well as to nervous system in 
general and to other organic systems.
4. Conclusions and further directions
Although we have known for some time that there are multipotent cells in the olfactory epi-
thelium and the olfactory bulb, only recently OM-MSC was identified at the lamina propria 
of OM. Since its discovery, most of the studies that addressed OM-MSC focused on its com-
plete characterization and few studies have yet applied these cells in order to determine their 
regenerative capacity. The use of these cells presents clear technical advantages due to their 
location and their collection can be easily made in the donors under anaesthesia and practi-
cally without any side effect. In addition, besides its high versatility and clonogenic activity, 
OM-MSC may be used for autologous transplants, circumventing possible rejections at the 
site of application and ethical issues. Since MS-MSCs are submitted to an environment with 
continuous regenerative activity, it is understandable that they secrete higher levels of neuro-
trophic and myelinating factors when compared to MSCs with other origins. Thus, OM-MSCs 
appear as a robust candidate for the approach to PNI cases when compared to other MSCs 
that do not achieve significant success in promoting nerve growth through the glial scar. The 
regeneration of the peripheral nerve has been the subject of multiple studies and there are 
many therapeutic techniques currently under development. Despite this, and considering the 
restrictions still observed in these approaches, regenerative medicine is one of the options 
with higher potential to achieve success in this type of lesions. Although several types of stem 
cells and MSCs are already under study, the OM-MSCs, their identified characteristics and 
preliminary results observed after their application, make them a promise in regenerative 
medicine in general and, specifically, a revolutionary approach to PNI lesions or demyelinat-
ing diseases and in situations in which neuroprotection or neurite outgrowth is important 
for repair. In this moment of rapid expansion of the knowledge we have about OM-MSCs, 
the next steps will have to include a complete and unambiguous characterization of these 
cells, their secretome and their metabolome and a precise determination of their regenera-
tive potential in different tissues, specifically in the peripheral nerve, after isolation from the 
remaining OM cells. Finally, it will be necessary to explore their use associated with differ-
ent biomaterials (something that has not yet been done), growth factors and even other cells 
whose associations have already been shown to be effective, such as OECS.
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